MAIA Biotechnology ends at-the-market stock sales agreement with H.C. Wainwright
MAIA Biotechnology suspended sales of its common stock under an at-the-market offering agreement with H.C. Wainwright & Co. and gave notice that it is terminating the agreement, effective seven business days after May 14, 2026. Under the program, the company has sold 3,116,012 shares for gross proceeds of approximately $5,680,924 since the March 28, 2025 prospectus supplement covering up to $11,200,000. The filing does not give a reason for the termination, and ending the program means the company will no longer sell new shares through this channel.
Key points
- Agreement dated February 14, 2024, with H.C. Wainwright & Co., LLC; sales suspended May 14, 2026
- Termination effective seven business days after May 14, 2026
- Shares sold under the program: 3,116,012 for gross proceeds of approximately $5,680,924
- Prospectus supplement dated March 28, 2025 covered up to $11,200,000
The filing
Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 14, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.